Physician profile
David Vanderheiden
NPI 1790779247
$4,027.84
in general payments reported to CMS, 2019-2025
22 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $588 · 2021: $673 · 2022: $309 · 2023: $703 · 2024: $173 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112 · Education: $56.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.93 |
| Education | $56.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $985.97 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $787.85 | 2019-2021 | |
| Novo Nordisk INC | $485.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $400.53 | 2019-2021 | |
| Amarin Pharma, INC. | $273.05 | 2019-2021 | |
| Pfizer INC. | $185.06 | 2019-2023 | |
| Amgen INC. | $166.56 | 2019-2023 | Repatha |
| Si-Bone, INC. | $154.48 | 2023 | |
| Corcept Therapeutics | $134.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.73 | 2020-2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $105.38 | 2019 | |
| Esperion Therapeutics, INC. | $41.12 | 2021 | |
| Redhill Biopharma INC. | $25.77 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.95 | 2019-2020 | |
| Shield Therapeutics INC | $23.36 | 2023 | Accrufer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.86 | 2023 | Quviviq |
| Exact Sciences Corporation | $19.68 | 2025 | Cologuard Collection Kit |
| Nevro Corp. | $18.70 | 2022 | |
| Phadia US INC. | $13.97 | 2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2021 | |
| Shire North American Group INC | $12.12 | 2019 | |
| Kerecis Limited | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vanderheiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.